0001415889-24-004005.txt : 20240215
0001415889-24-004005.hdr.sgml : 20240215
20240215204100
ACCESSION NUMBER: 0001415889-24-004005
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240213
FILED AS OF DATE: 20240215
DATE AS OF CHANGE: 20240215
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Seehra Jasbir
CENTRAL INDEX KEY: 0001732369
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39264
FILM NUMBER: 24645551
MAIL ADDRESS:
STREET 1: C/O ELOXX PHARMACEUTICALS, INC.
STREET 2: 950 WINTER STREET
CITY: WALTHAM
STATE: MA
ZIP: 02451
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Keros Therapeutics, Inc.
CENTRAL INDEX KEY: 0001664710
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 811173868
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 1050 WALTHAM STREET, SUITE 302
CITY: LEXINGTON
STATE: MA
ZIP: 02421
BUSINESS PHONE: 617-314-6297
MAIL ADDRESS:
STREET 1: 1050 WALTHAM STREET, SUITE 302
CITY: LEXINGTON
STATE: MA
ZIP: 02421
4
1
form4-02162024_010254.xml
X0508
4
2024-02-13
0001664710
Keros Therapeutics, Inc.
KROS
0001732369
Seehra Jasbir
C/O KEROS THERAPEUTICS, INC.
1050 WALTHAM STREET, SUITE 302
LEXINGTON
MA
02421
true
true
false
false
CHIEF EXECUTIVE OFFICER
0
Employee Stock Option (right to buy)
56.18
2024-02-13
4
A
0
125000
0
A
2034-02-12
Common Stock
125000
125000
D
25% of the shares subject to the option shall vest on February 13, 2025, and 6.25% of the shares subject to the option shall vest in equal quarterly installments thereafter, subject to the Reporting Person continuing to provide service through each such date.
/s/ Keith Regnante, Attorney-in-Fact
2024-02-15